Long-Term Outcomes After CAR-T Therapy for CLL
May 28, 2025
CAR-T therapy can provide very long remissions in a subset of patients with relapsed / refractory CLL who responded for at least one year.
CAR-T therapy can provide very long remissions in a subset of patients with relapsed / refractory CLL who responded for at least one year.
Lisocabtagene Maraleucel (liso-cel), a CAR-T therapy, is effective but only in a minority of chronic lymphocytic leukemia (CLL) patients.
CAR-T therapy is a potent cellular immune treatment that genetically trains an individual’s immune system to both recognize and attack cancerous cells.
An experimental CAR-T cell therapy made from healthy donor T cells is being tested in an ongoing phase 1 clinical trial to treat B Cell cancers.
Chimeric Antigen Receptor T-cell (CAR-T) therapy is a potent cellular immune treatment that genetically trains an individual’s immune system (specifically, the T-cells, a type of white blood cell) to both recognize and attack cancerous cells.
Chimeric antigen receptor T-cell (CAR-T) therapy can provide durable remissions in a subset of patients with Richter’s transformation.
Chimeric antigen receptor T-cell (CAR-T) therapy can provide durable remissions in a subset of patients with Richter’s transformation.
This research shows that senescence (biological aging) can occur in CAR-T cells, reducing their ability to kill cancer cells.
and President, interviewed Dr. Alexey Danilov, Associate Director of the Toni Stephenson Lymphoma Center at City of Hope in Duarte, CA. They discussed the development of Richter transformation after chimeric antigen receptor T-cell (CAR-T) therapy.
© 2025 CLL Society. All Rights Reserved.
Legal | Privacy Policy | Corporate Giving Policy
Terms & Conditions | Report a Bug | Site Design
CLL Society Inc. is a patient–centric, physician–curated nonprofit organization focused on patient education, support, and research. Dedicated to addressing the unmet needs of the chronic lymphocytic leukemia (CLL) and related blood cancer communities, we explain the rapidly changing therapeutic landscape and the importance of clinical trials, support and build patient networks, engage in research, and educate providers and patients.
CLL Society is a registered 501(c)(3) tax-exempt nonprofit organization. All donations are tax-deductible to the greatest extent as allowed under federal law. CLL Society’s tax ID number is 46-4131354.
1454 Melrose Avenue, Ste. 1-247
Chula Vista, CA 91911